713 related articles for article (PubMed ID: 21349409)
21. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
Thapi S; Baeg K; Kim MK; Gallagher EJ
Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
[TBL] [Abstract][Full Text] [Related]
22. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors.
Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S
Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537
[TBL] [Abstract][Full Text] [Related]
23. [Results of a nationwide survey of gastrointestinal tumors in Japan].
Ito T; Tanaka M; Imamura M;
Nihon Geka Gakkai Zasshi; 2008 May; 109(3):128-32. PubMed ID: 18536315
[TBL] [Abstract][Full Text] [Related]
24. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
25. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
26. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
Kessel E; Naparst M; Alpert N; Diaz K; Ahn E; Wolin E; Taioli E; Kim MK
Pancreas; 2021 Jan; 50(1):29-36. PubMed ID: 33370020
[TBL] [Abstract][Full Text] [Related]
27. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas.
Kamp K; Damhuis RA; Feelders RA; de Herder WW
Endocr Relat Cancer; 2012 Feb; 19(1):95-9. PubMed ID: 22194442
[TBL] [Abstract][Full Text] [Related]
28. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy.
Gustafsson BI; Siddique L; Chan A; Dong M; Drozdov I; Kidd M; Modlin IM
Int J Oncol; 2008 Dec; 33(6):1121-31. PubMed ID: 19020744
[TBL] [Abstract][Full Text] [Related]
29. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.
Oberg K; Astrup L; Eriksson B; Falkmer SE; Falkmer UG; Gustafsen J; Haglund C; Knigge U; Vatn MH; Välimäki M;
Acta Oncol; 2004; 43(7):626-36. PubMed ID: 15545183
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
[TBL] [Abstract][Full Text] [Related]
31. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.
Schimmack S; Svejda B; Lawrence B; Kidd M; Modlin IM
Langenbecks Arch Surg; 2011 Mar; 396(3):273-98. PubMed ID: 21274559
[TBL] [Abstract][Full Text] [Related]
32. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
33. IL-6-174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Berković MC; Jokić M; Marout J; Radosević S; Zjacić-Rotkvić V; Kapitanović S
Exp Mol Pathol; 2007 Dec; 83(3):474-9. PubMed ID: 17950274
[TBL] [Abstract][Full Text] [Related]
34. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
[TBL] [Abstract][Full Text] [Related]
35. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
36. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
Martin JA; Warner RR; Wisnivesky JP; Kim MK
Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
[TBL] [Abstract][Full Text] [Related]
37. [Surgical prognostic factors of gastroenteropancreatic neuroendocrine tumors (GEP NET)].
Medrano-Guzmán R; Alvarado-Cabrero I; González-Rodríguez D; López-García SC; Páez-Agraz F
Rev Med Inst Mex Seguro Soc; 2012; 50(3):243-8. PubMed ID: 23182252
[TBL] [Abstract][Full Text] [Related]
38. Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study.
Abdel-Rahman O; Fazio N
Pancreas; 2021 May-Jun 01; 50(5):727-731. PubMed ID: 34016894
[TBL] [Abstract][Full Text] [Related]
39. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
40. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.
Ito T; Igarashi H; Nakamura K; Sasano H; Okusaka T; Takano K; Komoto I; Tanaka M; Imamura M; Jensen RT; Takayanagi R; Shimatsu A
J Gastroenterol; 2015 Jan; 50(1):58-64. PubMed ID: 24499825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
